Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

2(40%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

20%

Ph phase_3

20%

Ph phase_4

60%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 2Efficacy & side effects

1(20.0%)

Phase 3Large-scale testing

1(20.0%)

Phase 4Post-market surveillance

3(60.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(3)

Detailed Status

Completed3

Recruiting2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 21 (20.0%)

Phase 31 (20.0%)

Phase 43 (60.0%)

Trials by Status

recruiting240%

completed360%

Recent Activity

2 active trials

Showing 5 of 5

recruitingphase_3

Ebastine Versus Mebeverine in IBS Patients

NCT05815602

recruitingphase_2

Effect of Ebastine in Patients With Diarrhea Predominant Irritable Bowel Syndrome

NCT07114055

completedphase_4

Clinical Trials (5)

Showing 5 of 5 trials

NCT05815602Phase 3

Ebastine Versus Mebeverine in IBS Patients

Recruiting

NCT07114055Phase 2

Effect of Ebastine in Patients With Diarrhea Predominant Irritable Bowel Syndrome

Recruiting

NCT01908465Phase 4

Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial

Completed

NCT01144832Phase 4

Irritable Bowel Syndrome (IBS) Treatment With H1-receptor Antagonists

Completed

NCT01940393Phase 4

Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5